한빛사논문
- 조회271
Cheonjung Kim a,1, Yong Kyoung Yoo b,1, Na Eun Lee a,d, Junwoo Lee a, Kang Hyeon Kim a, Seungmin Lee a,c, Jinhwan Kim a, Seong Jun Park a, Dongtak Lee c, Sang Won Lee c, Kyo Seon Hwang e, Sung Il Han f, Dongho Lee f, Dae Sung Yoon c,*, Jeong Hoon Lee a,*
a Department of Electrical Engineering, Kwangwoon University, Seoul, 01897, Republic of Korea b Department of Electronic Engineering, Catholic Kwandong University, 24, Beomil-ro 579 beon-gil, Gangneung-si, Gangwon-do, 25601, Republic of Korea c School of Biomedical Engineering, Korea University, Seoul, 02841, Republic of Korea d Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, 02841, Republic of Korea e Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea f CALTH Inc., Changeop-ro 54, Seongnam, Gyeonggi, 13449, Republic of Korea
* Corresponding author.
1 These authors contributed equally.
Abstract
A lateral flow assay (LFA) platform is a powerful tool for point-of-care testing (POCT), especially for self-testing. Although the LFA platform provides a simple and disposable tool for Coronavirus disease of 2019 (COVID-19) antigen (Ag) and antibody (Ab) screening tests, the lower sensitivity for low virus titers has been a bottleneck for practical applications. Herein, we report the combination of a microfluidic paper-based nanoelectrokinetic (NEK) preconcentrator and an LFA platform for enhancing the sensitivity and limit of detection (LOD). Biomarkers were electrokinetically preconcentrated onto a specific layer using the NEK preconcentrator, which was then coupled with LFA diagnostic devices for enhanced performance. Using this nanoelectrokinetic-assisted LFA (NEK-LFA) platform for self-testing, the severe acute respiratory syndrome coronavirus 2 Immunoglobulin G (SARS-CoV-2 IgG) sample was preconcentrated from serum samples. After preconcentration, the LOD of the LFA was enhanced by 32-fold, with an increase in analytical sensitivity (16.4%), which may offer a new opportunity for POCT and self-testing, especially in the COVID-19 pandemic and endemic global context.
논문정보
- Research article
- 2022년 05월 (BRIC 등록일 2022-08-12)
- 국내 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기
